IR Materials

Dec 16, 2022

[Analyst Report] Value of mRNA platform growing

- Positive findings from Moderna’s Phase-II study of an mRNA cancer vaccine have raised expectations towards the versatility of mRNA platforms.

- BioNTech is also expected to announce clinical results for its cancer vaccines—one in a Phase-I trial for solid cancer patients and another in a Phase-II trial for melanoma patients—keeping mRNA-related momentum alive.

- ST Pharm is a latecomer to the mRNA segment, but owns major patents relating to an mRNA platform. If its mRNA COVID vaccine (a Phase-I trial is underway), demonstrates safety and efficacy, the value of ST Pharm’s mRNA platform should rise.